Generic Name: tafasitamab

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Morphosis/Incyte

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Monjuvi is a CD19-directed monoclonal antibody approved for the treatment of relapsed or refractory (nonresponsive) diffuse large B-cell lymphoma in combination with Revlimid (lenalidomide).

General Info

Monjuvi is an engineered antibody that binds to the CD19 protein on B cells that grow out of control in leukemia and lymphoma. The L-MIND study showed that 55% of people with relapsed or refractory DLBCL who were treated with Monjuvi plus Revlimid followed by Revlimid alone experienced remission, including 37% with complete responses. The median duration of response was 21.7 months. Monjuvi was first approved in July 2020.


Dosing Info:

Monjuvi is administered as an intravenous infusion in combination with Revlimid for up to 12 cycles followed by Monjuvi alone until disease progression or unacceptable side effects.

Side Effects

Common adverse reactions include fatigue, diarrhea, fever, edema (swelling), cough and respiratory infections. Monjuvi can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. More serious side effects may include infusion reactions and severe blood cell deficiencies. Monjuvi can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: August 10, 2020